HFS
INKT icon

Horizon Financial Services’s MiNK Therapeutics INKT Stock Holding History

Horizon Financial Services’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-160
Closed -$1.78K – 379
2025
Q4 		$1.78K Buy
+160
New +$2.07K ﹤0.01% 318

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Horizon Financial Services's INKT Position: Q1 2026 in Review

Horizon Financial Services sold out of MiNK Therapeutics (INKT) in Q1 2026, closing a stake of 160 shares — an estimated $1.78K sold.

Horizon Financial Services first reported a position in INKT in Q4 2025 and held it in 1 quarter. The position peaked at $1.78K in Q4 2025. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Horizon Financial Services reported no remaining MiNK Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Horizon Financial Services sold 160 MiNK Therapeutics shares in Q1 2026, an estimated $1.78K.
  • Horizon Financial Services first reported a position in MiNK Therapeutics in Q4 2025 and held it in 1 quarter.
  • Horizon Financial Services's MiNK Therapeutics position peaked at $1.78K in Q4 2025.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Horizon Financial Services's 13F filing for Q1 2026, filed 15 Apr 2026.